Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Moderate Buy" from Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $15.14.

Several research analysts have recently issued reports on the stock. Oppenheimer lowered their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, November 22nd. Truist Financial initiated coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They set a "buy" rating and a $21.00 price target for the company. UBS Group initiated coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $20.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Finally, Royal Bank of Canada dropped their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an "outperform" rating on the stock in a report on Monday, November 25th.

Insider Activity at Perspective Therapeutics

In related news, Director Heidi Henson bought 25,975 shares of Perspective Therapeutics stock in a transaction dated Wednesday, December 4th. The stock was purchased at an average cost of $3.85 per share, with a total value of $100,003.75. Following the transaction, the director now directly owns 25,975 shares of the company's stock, valued at approximately $100,003.75. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Johan M. Spoor acquired 8,000 shares of Perspective Therapeutics stock in a transaction on Wednesday, December 4th. The shares were purchased at an average cost of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now owns 36,257 shares of the company's stock, valued at $136,688.89. This trade represents a 28.31 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 67,570 shares of company stock valued at $256,789 over the last 90 days. Insiders own 3.52% of the company's stock.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC bought a new stake in Perspective Therapeutics during the 3rd quarter worth approximately $57,000. US Bancorp DE lifted its stake in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics in the second quarter worth approximately $117,000. Point72 DIFC Ltd purchased a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at $118,000. Finally, Intech Investment Management LLC bought a new position in shares of Perspective Therapeutics during the third quarter valued at about $137,000. Institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded up $0.11 during midday trading on Wednesday, hitting $3.25. The company's stock had a trading volume of 502,853 shares, compared to its average volume of 883,877. The company has a 50-day moving average price of $7.43 and a two-hundred day moving average price of $10.96. Perspective Therapeutics has a 1-year low of $2.70 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million for the quarter. Analysts forecast that Perspective Therapeutics will post -0.88 EPS for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.